• 1
    Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34: 768773.
  • 2
    Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004; 19: 253267.
  • 3
    Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl 2007; 13: 13661371.
  • 4
    Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890895.
  • 5
    Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. HEPATOLOGY 2007; 45: 549559.
  • 6
    Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007; 102: 19031909.
  • 7
    Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. HEPATOLOGY 2002; 35: 716721.
  • 8
    Quero JC, Schalm SW. Subclinical hepatic encephalopathy. Semin Liver Dis 1996; 16: 321328.
  • 9
    Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 573583.
  • 10
    Weissenborn K, Giewekemeyer K, Heidenreich S, Bokemeyer M, Berding G, Ahl B. Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 2005; 20: 359367.
  • 11
    Montagnese S, Amodio P, Morgan MY. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. Metab Brain Dis 2004; 19: 281312.
  • 12
    Kamath PS. The need for better clinical trials. HEPATOLOGY 2008; 48: 13.
  • 13
    Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005; 42 Suppl: S4553.
  • 14
    Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. HEPATOLOGY 2002; 35: 357366.
  • 15
    Bajaj JS, Hafeezullah M, Zadvornova Y, Martin E, Schubert CM, Gibson DP, et al. The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol 2009; 104: 898905.
  • 16
    Bajaj J, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. HEPATOLOGY 2009. DOI: 10.1002/hep.23128. Available at:
  • 17
    Groeneweg M, Moerland W, Quero JC, Hop WC, Krabbe PF, Schalm SW. Screening of subclinical hepatic encephalopathy. J Hepatol 2000; 32: 748753.
  • 18
    Weissenborn K, Tietge UJ, Bokemeyer M, Mohammadi B, Bode U, Manns MP, et al. Liver transplantation improves hepatic myelopathy: evidence by three cases. Gastroenterology 2003; 124: 346351.
  • 19
    Jover R, Company L, Gutierrez A, Zapater P, Perez-Serra J, Girona E, et al. Minimal hepatic encephalopathy and extrapyramidal signs in patients with cirrhosis. Am J Gastroenterol 2003; 98: 15991604.
  • 20
    Ferenci P. Wilson's disease. Clin Gastroenterol Hepatol 2005; 3: 726733.
  • 21
    Krieger S, Jauss M, Jansen O, Theilmann L, Geissler M, Krieger D. Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. Gastroenterology 1996; 111: 147155.
  • 22
    Qu B, Liu C, Guo L, Yang Y, Li JH, Yu L, et al. The role of liver transplantation in the treatment of hepatic myelopathy: case report with review of the literature. Transplant Proc 2009; 41: 19871989.
  • 23
    Bechar M, Freud M, Kott E, Kott I, Kravvic H, Stern J, et al. Hepatic cirrhosis with post-shunt myelopathy. J Neurol Sci 1970; 11: 101107.
  • 24
    Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 19681976.
  • 25
    Hassanein T, Blei AT, Perry W, Hilsabeck R, Stange J, Larsen FS, et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol 2009; 104: 13921400.
  • 26
    Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2: 8184.
  • 27
    Ortiz M, Cordoba J, Doval E, Jacas C, Pujadas F, Esteban R, et al. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther 2007; 26: 859867.
  • 28
    Stewart CA, Smith GE. Minimal hepatic encephalopathy. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 677685.
  • 29
    Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008; 14: 36093615.
  • 30
    Weissenborn K, Heidenreich S, Ennen J, Ruckert N, Hecker H. Attention deficits in minimal hepatic encephalopathy. Metab Brain Dis 2001; 16: 1319.
  • 31
    Amodio P, Campagna F, Olianas S, Iannizzi P, Mapelli D, Penzo M, et al. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol 2008; 49: 346353.
  • 32
    Wechsler D. Wechsler Adult Intelligence Scale-III. San Antonio: Psychological Corp., 1999.
  • 33
    Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009; 29: 629635.
  • 34
    Sorrell JH, Zolnikov BJ, Sharma A, Jinnai I. Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation. Psychiatry Clin Neurosci 2006; 60: 174181.
  • 35
    Mooney S, Hasssanein TI, Hilsabeck RC, Ziegler EA, Carlson M, Maron LM, et al. Utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in patients with end-stage liver disease awaiting liver transplant. Arch Clin Neuropsychol 2007; 22: 175186.
  • 36
    Duff K, Humphreys Clark JD, O'Bryant SE, Mold JW, Schiffer RB, Sutker PB. Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: sensitivity, specificity, and positive and negative predictive powers. Arch Clin Neuropsychol 2008; 23: 603612.
  • 37
    Mardini H, Saxby BK, Record CO. Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant. Gastroenterology 2008; 135: 15821590.
  • 38
    Garavan H, Ross TJ, Stein EA. Right hemispheric dominance of inhibitory control: an event-related functional MRI study. Proc Natl Acad Sci U S A 1999; 96: 83018306.
  • 39
    Bajaj JS, Hafeezullah M, Franco J, Varma RR, Hoffmann RG, Knox JF, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008; 135: 15911600.
  • 40
    Bajaj JS, Saeian K, Verber MD, Hischke D, Hoffmann RG, Franco J, et al. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol 2007; 102: 754760.
  • 41
    Amodio P, Del Piccolo F, Marchetti P, Angeli P, Iemmolo R, Caregaro L, et al. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. HEPATOLOGY 1999; 29: 16621667.
  • 42
    Amodio P, Marchetti P, Del Piccolo F, Rizzo C, Iemmolo RM, Caregaro L, et al. Study on the Sternberg paradigm in cirrhotic patients without overt hepatic encephalopathy. Metab Brain Dis 1998; 13: 159172.
  • 43
    Masini A, Efrati C, Merli M, Nicolao F, Amodio P, Del Piccolo F, et al. Effect of blood ammonia elevation following oral glutamine load on the psychometric performance of cirrhotic patients. Metab Brain Dis 2003; 18: 2735.
  • 44
    Van der Rijt CC, Schalm SW, De Groot GH, De Vlieger M. Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol 1984; 57: 423426.
  • 45
    Kullmann F, Hollerbach S, Holstege A, Scholmerich J. Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials. J Hepatol 1995; 22: 101110.
  • 46
    Yang SS, Wu CH, Chiang TR, Chen DS. Somatosensory evoked potentials in subclinical portosystemic encephalopathy: a comparison with psychometric tests. HEPATOLOGY 1998; 27: 357361.
  • 47
    Saxena N, Bhatia M, Joshi YK, Garg PK, Dwivedi SN, Tandon RK. Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver 2002; 22: 190197.
  • 48
    Saxena N, Bhatia M, Joshi YK, Garg PK, Tandon RK. Auditory P300 event-related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: a follow-up study. J Gastroenterol Hepatol 2001; 16: 322327.
  • 49
    Kugler CF, Lotterer E, Petter J, Wensing G, Taghavy A, Hahn EG, et al. Visual event-related P300 potentials in early portosystemic encephalopathy. Gastroenterology 1992; 103: 302310.
  • 50
    Davies MG, Rowan MJ, MacMathuna P, Keeling PW, Weir DG, Feely J. The auditory P300 event-related potential: an objective marker of the encephalopathy of chronic liver disease. HEPATOLOGY 1990; 12: 688694.
  • 51
    Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl 2009; 15: 184192.
  • 52
    Romero-Gomez M, Cordoba J, Jover R, del Olmo JA, Ramirez M, Rey R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. HEPATOLOGY 2007; 45: 879885.
  • 53
    Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007; 47: 6773.
  • 54
    Hassanein TI, Hilsabeck RC, Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci 2008; 53: 529538.
  • 55
    Pockros P, Hassanein T, Vierling J, Heuman D, Hillebrand D, Chojkier M, et al. Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs. Lactulose in the treatment of low-grade hepatic encephalopathy (HE) [Abstract]. J Hepatol 2009; 50(Suppl 1): S43.
  • 56
    Häussinger D, Cordoba J, Kircheis G. Definition and assessment of low grade hepatic encephalopathy. In: Haussinger D, Kircheis G, Schliess F, eds. Hepatic Encephalopathy and Nitrogen Metabolism. Dordecht: Springer-Verlag, 2006.
  • 57
    Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 27182723.